Switching From Tirzepatide to Retatrutide: What's Actually Possible in 2026

By The RX Index Editorial Team

Switching from tirzepatide to retatrutide isn't possible with a regular U.S. prescription yet. Retatrutide isn't FDA-approved, and there's no approved dose conversion. The two documented medical paths are a Lilly clinical trial or expanded access—a doctor's request for treatment outside a trial. Each has strict rules; a weight-loss stall alone doesn't qualify you. (FDA; access record)

What changes that answer for you:

• Your BMI is 35 or higher despite taking and tolerating the highest available dose of a weight-management medicine, and at least two serious or life-threatening weight-related conditions are being treated. Expanded access may be worth asking your doctor about. Body mass index (BMI) compares weight to height; the full checklist has three other requirements.
• You're interested in a trial. Ask the study team whether it is enrolling and how your current medicine affects eligibility. TRIUMPH-5, the direct comparison study, is not enrolling. Do not stop treatment to copy its screening rules.
• You already bought "retatrutide" online. That label does not prove you have the medicine used in Lilly's studies. Jump to what to do now.

Here's the catch most switching guides skip. The two medical paths treat your current medicine differently. TRIUMPH-5 screened out recent weight-loss-drug use. Expanded access asks for proof that severe obesity persists despite treatment at the highest available dose. The map below shows what to ask about—not what to stop taking.

RX Index Decision Verdict: Start with a review of your current treatment, not an online conversion chart. Your prescriber can address the problem now and help you assess research or expanded access when relevant.

• Best for asking about expanded access: adults meeting all five requirements below, including BMI 35+ despite taking and tolerating the highest available dose, with at least two serious or life-threatening weight-related conditions under treatment.
• Not ideal for: choosing a "research" vial, changing a dose yourself, or replacing medical advice during pregnancy or pregnancy planning.
• The factor that matters most: why you want to switch. The reason guides the next step.

We can't pick a dose for you or get you retatrutide, and it isn't sold as an ordinary prescription medicine. What we can do is show you which paths to ask about, what the evidence does and doesn't say, and the exact words to bring to your prescriber.

Can you switch from tirzepatide to retatrutide right now?

No, not with a regular prescription. Retatrutide is an investigational drug, which means it's still being tested and no pharmacy, doctor, or telehealth company can fill an ordinary prescription for it. The two documented medical access paths here are a Lilly clinical trial or a doctor-requested expanded access program. Waiting for an FDA decision is a separate choice, not access today. (FDA; access record)

Here are the paths a tirzepatide user might hear about, checked October 15, 2026.

Expanded access isn't a waitlist. A trial isn't a back door. Both have strict rules. A review of your current care does not depend on either one opening up.

Talk to your clinician before using any provider tool if you're under 18, pregnant or planning a pregnancy, have type 1 diabetes, have a history of an eating disorder, or have a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN 2). Zepbound's label rules out that last group and people with a prior serious allergic reaction to tirzepatide or its ingredients. See GLP-1 hard contraindications.

The right next step isn't the same for everyone on tirzepatide. It depends on your state, your insurance and formulary (your plan's drug list), a shot or a pill, and your budget. FDA-approved and compounded medicines are different choices; a compounded drug needs a medical reason, not just a lower price. The RX Index's Find My GLP-1 Path tool asks a few quick questions, then shows suggested paths and providers to review. It's free, takes about 2 minutes, and needs no signup. It doesn't arrange retatrutide or check your personal coverage.

See which GLP-1 path fits you

Why do the two medical paths have different rules?

TRIUMPH-5 and expanded access answer different research and care questions. The retatrutide-versus-tirzepatide trial excluded people who took weight-loss drugs in the 90 days before screening. Lilly's expanded access record requires a BMI of 35+ despite taking and tolerating the highest available dose of a weight-management medicine. Neither rule is an instruction to change your treatment. (TRIUMPH-5; expanded access)

TRIUMPH-5 screened out recent weight-loss-drug use

TRIUMPH-5 compares the drugs in separate groups; it is not a study of people switching directly from ongoing tirzepatide. Its record excludes recent weight-loss drug use and big weight swings in the 90 days before screening.

Separately, that study isn't taking new people now. Lilly lists it as completed enrollment.

Do not stop tirzepatide for 90 days to copy a study's screening rule. Ask your prescriber and the study team before changing anything.

Why stopping is the trap

Stopping treatment can bring weight back. In Zepbound's withdrawal study, people who'd lost weight during 36 weeks on tirzepatide were assigned either to continue or to switch to a placebo, a dummy shot. Over the next 52 weeks, the placebo group gained 14.0% relative to their weight at that switch. People who stayed on tirzepatide lost another 5.5% from that same point (Zepbound prescribing information, revised August 2026). This does not predict how much someone would gain during a 90-day break.

So stopping on your own to chase a trial can backfire. You can regain weight, and a weight change over 5 kg (about 11 lb) would also conflict with TRIUMPH-5's screening rule. That study is already closed to new participants. It's like quitting your job to apply for one that may not be hiring.

The expanded access door wants your tirzepatide history

Expanded access is a way for a doctor to ask a drugmaker for an unapproved medicine for one patient who can't join a trial. Lilly's public record lists five requirements, and all five must be met. Your treatment history helps your doctor assess that checklist; it is not a ticket to automatic approval. The full checklist is further down.

Say you're 46, on Zepbound 10 mg, with a BMI of 32 and no other conditions. You do not meet the expanded-access BMI requirement, and TRIUMPH-5 is not enrolling. A different study would need its own eligibility check. Your current-care options are in the "why do you want to switch?" section.

Is there a tirzepatide-to-retatrutide dose conversion?

No. Retatrutide has no FDA-approved label, and the primary sources we checked don't establish any milligram conversion or switching schedule from tirzepatide. The TRIUMPH-1 and TRIUMPH-5 records do not validate those online conversion charts.

Here's what the evidence does and doesn't cover for someone already on tirzepatide.

A trial dose isn't a switching dose

A study schedule tells researchers how to give a drug inside that study. It doesn't tell anyone what dose fits a person coming off a different drug outside the study. That's the gap the online charts skip.

A screening rule isn't a washout schedule

Screening is the study team checking whether you fit the rules. A 90-day rule is a filter, not medical advice to stop treatment. The conflicting schedules on peptide sites do not fill the gap in the evidence. Neither trial record provides a consumer switching schedule.

For the full drug-versus-drug comparison, see Retatrutide vs Tirzepatide.

Would retatrutide work better than tirzepatide for you?

The studies we checked cannot predict what you would gain by switching. The trial that compares the drugs directly, TRIUMPH-5, lists a target enrollment of 800 adults and measures weight at 80 weeks. Its registry lists no results as of October 15, 2026, and its main data collection is estimated to finish in November 2026. Separate trials cannot establish which drug works better. (Registry)

Here are the two drugs' main weight-loss trials in adults without diabetes, side by side. They studied different people, for different lengths of time. The doses identify study groups, not a switching plan.

Subtracting these results does not tell us retatrutide's advantage over tirzepatide. Different groups, follow-up times, and analyses remain different after subtracting placebo. The published retatrutide difference is 21.0 points; subtracting its rounded percentages gives 21.1, which is not the same as the reported statistical estimate.

The 28.3% headline answers a different question: what the study estimates would happen if all participants stayed on their assigned treatment, with allowed changes, and did not use prohibited weight-loss drugs. It does not simply count only the people who finished. (Lilly's analysis definitions) Neither figure forecasts what you'd lose after switching. Our retatrutide weight loss results page shows the full numbers.

The trial results came with trade-offs

Retatrutide adds a third target, the glucagon receptor. That does not prove the added target caused a particular side effect. In Lilly's May 21, 2026 TRIUMPH-1 report:

• Dysesthesia (an odd skin feeling, like tingling or tenderness): 12.5% on 12 mg vs 0.9% on placebo. Zepbound's label reports 0.4% at 15 mg versus 0.1% on placebo in pooled Studies 1 and 2.
• Stopped because of side effects: 11.3% on 12 mg vs 4.9% on placebo. Zepbound's label reports 6.7% at 15 mg vs 3.4% on placebo in pooled Studies 1 and 2.
• Stomach side effects: nausea in 42.4% on 12 mg vs 14.8% on placebo.

These come from different trials, so treat them as signals, not a scorecard. Zepbound's pooled figures include adults with and without type 2 diabetes; TRIUMPH-1 excluded diabetes. They do not prove one drug is safer, and retatrutide is not a proven fix for side effects on tirzepatide. More on safety: Retatrutide side effects.

Say your weight has sat near the same number for three months on tirzepatide. A study in a different group can't tell you how much more you'd lose by changing drugs. Your own trend, dose history, and goals are where the conversation starts. See GLP-1 weight loss plateau for how to tell a stall from a non-response.

Why do you want to switch? Fix the real problem this month

Here are six reasons someone might want to switch. A stall, side effects, and a coverage problem each call for a different fix. Matching the next step to the reason is more useful than treating retatrutide as the answer to every problem.

If you stalled or maxed out

Zepbound's label tops out at 15 mg a week for adults, and 5, 10, and 15 mg are approved maintenance doses for weight management. Before any switch, the useful questions are: How long have you been at your current dose? Did you miss shots? Is the goal still the right one? Best GLP-1 after failing Zepbound walks through that review.

If your prescriber just refills your shot without looking at your dose history, a program with regular check-ins can help you work out the next step on an approved medicine. If you already have a prescriber who provides that care, check the manufacturer's self-pay options first; another membership is not required just to compare drug prices.

Ro lists Zepbound KwikPen cash prices of $299 per 28-day supply at 2.5 mg, $399 at 5 mg, and $449 at 7.5 to 15 mg with the manufacturer offer. The 2.5 mg price is not a maintenance-dose price. To keep the $449 refill price, Lilly requires the next purchase within 45 days of receiving the prior fill; Ro tells patients to complete its refill check-in within that window. Without the offer, Ro's Zepbound page lists $499 for 7.5 mg and $699 for 10–15 mg. That is a purchase deadline, not advice on when to inject. (Ro; Lilly terms, checked October 15, 2026)

Ro's membership is a separate charge: get started for $39 for the first month, then as low as $74/month with an annual plan paid upfront. After the first month, that annual plan is $888 billed at once for 12 months, not $74 charged each month. The ongoing month-to-month plan is $149. Ro says the $39 is refunded if you are not eligible; medication is charged separately after approval. (Ro pricing)

Membership includes provider messaging, check-ins, coaching, insurance support, and lab testing if needed. The drug price does not include membership or the KwikPen needles, which are sold separately; Lilly's terms also allow additional taxes and fees. A 28-day drug supply and a calendar-month membership are different billing periods. (Ro pricing; Lilly terms)

Before choosing the $888 prepayment, read the cancellation cutoff and refund terms shown at checkout. Ro's terms allow cancellation of future renewals but do not promise a prorated refund of a prepaid term. This is an optional paid care program, not retatrutide access.

See Zepbound care with Ro

If cost is the reason and you have insurance

Retatrutide is not a routine covered replacement for tirzepatide today. If you have insurance through work, check your plan's drug list and ask its pharmacy-benefits team whether Zepbound is covered before you pay cash. Ro also offers a free coverage report for Ozempic, Wegovy, and Zepbound autoinjector pens—not the Zepbound KwikPen. The report does not submit a treatment request or prescribe medicine. Ro's paid care program can handle prior-authorization paperwork if you join. Coverage isn't guaranteed. Your plan decides.

For Medicare or Medicaid questions, start with your own plan and prescriber rather than assuming a commercial-insurance service applies. The button below opens Ro's free report page, not its paid intake.

Check your Zepbound coverage with Ro

If a research-vial price is what tempted you

A low vial price is not a reason to bypass your clinician or choose an unapproved drug. Start by asking whether an FDA-approved treatment can meet your needs. The FDA says compounded drugs should be used only when an FDA-approved drug can't meet a patient's medical need, which is a call for your clinician. (FDA)

Embody offers compounded tirzepatide. Compounded drugs are not FDA-approved, the FDA doesn't review them for safety, effectiveness, or quality, and they aren't the same as Zepbound. FDA's current compounding guidance says tirzepatide is not on its shortage list and restrictions on making copies apply. A prescription alone does not establish that every compounded product meets those rules. (FDA compounding guidance)

If your clinician has identified a medical need for a compounded product, Embody is one program to compare—not a way to get retatrutide. Its homepage advertised compounded tirzepatide injections at a "flat rate" of $119/month on October 15, 2026. Its FAQ says the price depends on plan length (4, 12, 24, or 52 weeks). We could not verify which plan earns that headline price, the total due at checkout, or its renewal amount. Do not read it as a confirmed $119 month-to-month bill. Embody's public offer says it does not serve Louisiana and requires patients in Nebraska to be at least 19. State availability and clinical approval still need confirmation before payment.

Read the refund terms before paying. Embody's policy, updated August 25, 2026, makes purchases—including multi-month plans—nonrefundable except for provider-initiated medical disqualification, after deducting services already used. Cancellation must reach Embody at least 72 hours before the next billing date. Canceling does not recover unused prepaid months. Ask for the full-term price and renewal terms in writing first.

See Embody's current tirzepatide pricing

If tirzepatide treats your type 2 diabetes

Mounjaro is tirzepatide approved for type 2 diabetes (prescribing information). A weight-loss switching chart is not a diabetes plan. Keep your diabetes clinician in charge of any change, and bring your medicine list and recent glucose numbers.

Could expanded access apply to you?

Expanded access is not a normal prescription or a sign the drug is approved. It's a request your treating doctor makes to Lilly for one patient who can't join a trial. Lilly's public record lists five requirements, all of which must be met, and meeting them on paper doesn't guarantee access.

Here's the checklist, as posted in NCT07629401 (listed as Available, last update posted August 6, 2026), with what each item means for someone on tirzepatide. We rechecked the record on October 15, 2026.

The record also excludes anyone with a medical reason retatrutide would be unsafe for them. It says requests come from the treating doctor, and patients should go to their doctor rather than calling Lilly. Access depends on location, supply, and a case-by-case review. The record lists 1-800-LillyRx (1-800-545-5979) for the treating doctor's request—not a patient signup line. The FDA's expanded access page explains the doctor, drugmaker, FDA, and ethics-board steps, and suggests asking about costs up front.

Say you're 58, BMI 41 after a year on Zepbound 15 mg taken as prescribed, with type 2 diabetes and sleep apnea under treatment, and no study near you. Those facts give your doctor a reason to review the checklist, not enough to approve you. Your doctor still must assess dose tolerance, whether both conditions are serious or life-threatening, trial access, the discussion of all standard options, and any medical reason not to use retatrutide. The next step is your doctor's assessment and, when appropriate, a call to Lilly—not yours.

To look at research studies yourself, start with the drugmaker's listings, not a seller: Search Lilly's clinical studies. The records we checked list TRIUMPH-1 as completed and TRIUMPH-5 as active but not recruiting. That is not a count of every retatrutide study. Our retatrutide availability page covers the wider access picture.

What should you ask your prescriber before changing anything?

Bring the reason you want to switch, the exact product you take, and what's happened on it. That gives your clinician a real question to answer, so you don't have to lean on an online conversion chart.

You don't need the perfect medical wording. Start with this message, and write "unknown" for anything you don't know.

I am taking [exact product name, e.g., Zepbound, Mounjaro, or compounded tirzepatide] for [reason]. My prescribed dose is [copy the label in mg, or write "unknown"], and I have used this dose for [time]. My last dose was [date]. I'm asking about a change because of [weight trend, side effects, cost, coverage, or something else]. Before I change anything, can we review my current treatment and the options that fit my health needs? Please also tell me whether a retatrutide study or Lilly's physician-requested expanded access program (NCT07629401) is relevant for me. My height and weight are [numbers or "unknown"]. My other medicines and conditions are [list]. What should my plan be while we review this?

A photo of your prescription label helps your clinician if you're unsure of the product or dose. Don't turn syringe "units" into milligrams yourself.

What if you already bought or used "retatrutide"?

A vial labeled "retatrutide" is not proof it holds the medicine used in Lilly's studies. The FDA says retatrutide can't be compounded under federal law, and it has warned sellers who label it "for research purposes" while selling it for people to inject. Products like these are of unknown quality and may be harmful.

This isn't about judgment. A clinic-style website or a research label does not prove what is in a vial. In August 2026, Lilly filed six lawsuits against U.S. sellers, including med spas, a compounding pharmacy, and online "research-use" sellers. That enforcement action does not tell us the contents of a particular product you bought.

What to do now:

1. Tell your clinician exactly what you used, when, and how much. Keep the vial, label, and receipt.
2. If you think you may have been exposed to a harmful product, call Poison Help: 1-800-222-1222. Do not wait for symptoms. Have the container with you (HRSA).
3. For trouble breathing, collapse or loss of consciousness, or a seizure, call 911 right away (America's Poison Centers).
4. Report the product to the FDA through MedWatch.

For questions about side effects that aren't urgent, see Retatrutide side effects and How to avoid fake GLP-1 medications.

When could a normal switch be possible?

Not before FDA approval, and there's no approval date. In its July 23, 2026 update, Lilly said it plans to submit retatrutide to the FDA in the first quarter of 2027. That is a company filing plan, not an FDA decision date. Approval, pharmacy stock, price, and insurance coverage are separate questions.

One tip that costs nothing: keep a record of your tirzepatide doses, dates, and weights. If retatrutide is approved, plans may ask what you've already tried. That's our expectation, not a published plan rule. Either way, your doctor will want the history.

What we actually verified

We checked the FDA's unapproved-GLP-1 and compounding guidance, current tirzepatide labels, Lilly's retatrutide statements and trial listings, the official trial and expanded access records, the published TRIUMPH-1 abstract, and Ro's and Embody's public prices and terms. We checked what those sources say, not whether any online product is genuine.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

Last verified October 2026 — source checks completed October 15, 2026

• FDA: Retatrutide is not approved and can't be used in compounding. We read the current guidance and compounding rules on October 15, 2026.
• Expanded access record (NCT07629401): Listed as Available; last update posted August 6, 2026; criteria rechecked in the registry October 15, 2026.
• TRIUMPH-5 (NCT06662383): Active, not recruiting; no results posted; record updated July 20, 2026. Lilly's listing shows completed enrollment and no placebo. Checked October 15, 2026.
• Tirzepatide labels: Zepbound and Mounjaro prescribing information revised August 2026. We checked the relevant indications, Zepbound combination wording, half-life, trial results, and withdrawal results on October 15, 2026.
• TRIUMPH-1 results: We read Lilly's May 21, 2026 release and the published September 29, 2026 trial abstract on October 15, 2026. The weight-loss table uses the published abstract. The side-effect figures are explicitly from the May sponsor report; we could not inspect the later paper's full safety tables.
• Prices and terms: Public provider and manufacturer pages checked October 15, 2026. Ro membership, Zepbound KwikPen offer terms, and Embody's advertised price and refund policy. We did not complete an intake or payment; Embody's selected-plan total and renewal price were not verified.
• A conflict we found: Lilly's general FAQ, updated September 2026, still says retatrutide is legally available only through Lilly's trials. Lilly's own expanded access record lists a second, narrow path. We rely on the specific record for that exception.
• What we didn't do: call trial sites, test any product, enroll anyone, confirm a single person's eligibility, or test the finished page's copy control. No clinician reviewed this page.

How we judge providers and paths: Methodology.

Frequently asked questions

I'm on a high tirzepatide dose. Can I start retatrutide at an equal dose?

No approved equal dose exists. Your tirzepatide dose doesn't tell anyone where retatrutide should start. Anyone who gets retatrutide through a study or expanded access follows that program's medical plan, not a chart. (FDA)

How long should I wait after tirzepatide before starting retatrutide?

The sources we checked don't set a waiting period for this switch. TRIUMPH-5's 90-day rule was a screening filter, not a washout instruction. Ask your prescriber and the study team before you change your treatment. (TRIUMPH-5)

Should I increase my tirzepatide dose instead of switching?

That's a call for your prescriber. Zepbound's label allows up to 15 mg a week in adults, with 5, 10, and 15 mg listed for weight-management maintenance. A stall isn't automatic permission to raise the dose or change drugs. Ask for a review of your response, side effects, and goal.

Can I take tirzepatide and retatrutide together?

Don't combine them on your own. Zepbound's label says using it with other tirzepatide products or any GLP-1 receptor agonist is not recommended. The sources we checked do not establish a safe consumer overlap plan.

Can I switch from Zepbound or Mounjaro to retatrutide?

Both contain tirzepatide, so the answer is the same. There's no regular prescription switch yet. If Mounjaro treats your type 2 diabetes, keep your diabetes clinician in charge of any change. (Mounjaro label)

Can my doctor prescribe retatrutide off-label?

No. "Off-label" means using an FDA-approved drug in a way its label doesn't cover. Retatrutide is not an FDA-approved drug, so this is not ordinary off-label prescribing. A trial or expanded access is a different process (FDA).

Does "Available" on the expanded access record mean I qualify?

No. It describes the program's status, not your eligibility or a promise of supply. Your treating doctor has to review all five requirements and make the request. (access record)

Will retatrutide work if tirzepatide stopped working for me?

Nobody knows yet. No study we found tested retatrutide in people who didn't respond to tirzepatide. Your prescriber can also review other approved options now.

Is retatrutide stronger than tirzepatide?

The trial averages shown above were higher for retatrutide, but separate trials do not establish superiority or the extra loss after a switch. Subtracting each placebo result does not solve that problem. The head-to-head trial, TRIUMPH-5, is designed for a direct comparison; its registry had no results posted when checked October 15, 2026.

Will insurance pay for retatrutide, or is expanded access free?

There's no approved retail retatrutide product, and Lilly hasn't announced a commercial price. The expanded-access record does not quote your costs. FDA says an expanded-access sponsor may cover costs or charge allowed costs, and insurance often does not cover all of the care. Ask the requesting doctor which drug, visit, lab, and travel costs you'd pay before agreeing. (FDA)

What if I don't know my dose, BMI, or coverage?

Write "unknown" instead of guessing. Your pharmacy or prescription label can confirm the product and dose. Your clinician can check your height and weight, and your plan can answer coverage questions. You don't need a perfect number to start the conversation.

Is compounded retatrutide legal?

No. The FDA says retatrutide can't be used in compounding under federal law and isn't part of any FDA-approved drug. A clinic, pharmacy, or "research use only" label doesn't change that. (FDA)

What is "GLP-3"?

It's a nickname, not a real drug class. Lilly calls it scientifically inaccurate. Retatrutide is a "triple agonist," meaning it acts on three hormone receptors: GIP, GLP-1, and glucagon. Tirzepatide acts on two: GIP and GLP-1.

Sources

Checked October 15, 2026. Dates below identify source publications or updates, not new clinical results.

1. FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
2. ClinicalTrials.gov — Pre-approval Expanded Access of Retatrutide, NCT07629401 (update posted August 6, 2026)
3. ClinicalTrials.gov — TRIUMPH-5, NCT06662383 (update posted July 20, 2026)
4. Lilly Trials — TRIUMPH-5 listing
5. ClinicalTrials.gov — TRIUMPH-1, NCT05929066 (update posted August 21, 2026)
6. New England Journal of Medicine — TRIUMPH-1 published trial (published September 29, 2026; abstract inspected)
7. Eli Lilly — TRIUMPH-1 results release (May 21, 2026; source of the dated sponsor side-effect figures)
8. Eli Lilly — Retatrutide Phase 3 update and Q1 2027 submission plan (July 23, 2026)
9. Eli Lilly — What to know about retatrutide (updated September 2026)
10. Eli Lilly — Zepbound prescribing information (revised August 2026)
11. Eli Lilly — Mounjaro prescribing information (revised August 2026)
12. FDA — Expanded Access: Information for Patients
13. FDA — Understanding Unapproved Use of Approved Drugs "Off Label"
14. Eli Lilly — Lilly files six lawsuits against illegal retatrutide sellers (August 12, 2026)
15. FDA — Compounding policies after GLP-1 shortage resolution (current page includes April 1, 2026 policy clarification)
16. Ro — Weight loss program pricing
17. Ro — Zepbound program and refill-offer terms
18. Eli Lilly — Zepbound savings and self-pay terms
19. Ro — GLP-1 Insurance Coverage Checker
20. Ro — Terms of Use
21. Embody — Homepage pricing and FAQ
22. Embody — Subscription cancellation and refund policy (updated August 25, 2026)
23. Embody — Terms and Conditions
24. HRSA — Poison Help
25. America's Poison Centers — First aid for poisoning
26. FDA — MedWatch safety reporting
27. Embody — Public offer and state-availability FAQ (provider-stated; checked October 15, 2026)
28. The RX Index — How Find My Path works and the live template offer (checked October 15, 2026)